MaxCyte Inc (MXCT) is -7.37% away from 50-day simple Moving Average despite all headwinds

MaxCyte Inc (NASDAQ: MXCT) open the trading on Wednesday, with great promise as it jumped 3.41% to $4.25, before settling in for the price of $4.11 at the close. Taking a more long-term approach, MXCT posted a 52-week range of $2.45-$5.55.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


It was noted that the giant of the Healthcare sector posted annual sales growth of 20.83% over the last 5 years. Meanwhile, its Annual Earning per share during the time was -16.20%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -32.82%. This publicly-traded company’s shares outstanding now amounts to $103.96 million, simultaneously with a float of $91.36 million. The organization now has a market capitalization sitting at $442.55 million. At the time of writing, stock’s 50-day Moving Average stood at $4.57, while the 200-day Moving Average is $4.22.

MaxCyte Inc (MXCT) Ownership Facts and Figures

Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Medical Devices industry. MaxCyte Inc’s current insider ownership accounts for 12.27%, in contrast to 71.00% institutional ownership. According to the most recent insider trade that took place on Mar 26 ’24, this organization’s Director sold 5,000 shares at the rate of 4.41, making the entire transaction reach 22,025 in total value, affecting insider ownership by 120,583. Preceding that transaction, on Jan 26 ’24, Company’s Director sold 5,000 for 5.12, making the whole transaction’s value amount to 25,585. This particular insider is now the holder of 120,583 in total.

MaxCyte Inc (MXCT) Earnings and Revenue Records

So, what does the last quarter earnings report of the company that was made public on 12/30/2023 suggests? It has posted -$0.05 earnings per share (EPS) beating the forecaster’s viewpoint (set at -$0.07) by $0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.

MaxCyte Inc’s EPS decrease for this current 12-month fiscal period is -32.82% and is forecasted to reach -0.41 in the upcoming year.

MaxCyte Inc (NASDAQ: MXCT) Trading Performance Indicators

Let’s observe the current performance indicators for MaxCyte Inc (MXCT). It’s Quick Ratio in the last reported quarter now stands at 9.97. The Stock has managed to achieve an average true range (ATR) of 0.22. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 10.72.

In the same vein, MXCT’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.37, a figure that is expected to reach -0.12 in the next quarter, and analysts are predicting that it will be -0.41 at the market close of one year from today.

Technical Analysis of MaxCyte Inc (MXCT)

[MaxCyte Inc, MXCT] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 25.15% While, its Average True Range was 0.21.

Raw Stochastic average of MaxCyte Inc (MXCT) in the period of the previous 100 days is set at 45.93%, which indicates a major rise in contrast to 36.84% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 41.42% that was lower than 58.31% volatility it exhibited in the past 100-days period.